Human erythropoietin (hEPO) is a vital glycoprotein hormone that regulates erythropoiesis—the production of red blood cells. While recombinant hEPO proteins have long been the clinical standard for treating anemia associated with chronic kidney disease (CKD) and chemotherapy, hEPO messenger RNA (mRNA) technology represents a paradigm shift. By delivering the genetic blueprint for hEPO directly to the patient's cells, mRNA-based therapies enable the body to serve as its own "bioreactor," producing hEPO with natural post-translational modifications and a potentially superior pharmacokinetic profile. At CD BioGlyco, we leverage our extensive expertise in glycobiology and nucleic acid chemistry to provide high-purity hEPO mRNA synthesis services. Our platform is designed to overcome traditional manufacturing hurdles, offering researchers and drug developers a reliable source of optimized, translatable mRNA for protein replacement therapy and gene delivery studies.
At CD BioGlyco, our hEPO mRNA synthesis service is a cornerstone of our therapeutic nucleic acid development platform. We provide a full-spectrum therapeutic oligonucleotide synthesis service that translates complex genetic designs into high-performing therapeutic candidates. Our expanded scope includes:
We begin by analyzing the target hEPO sequence. Using proprietary algorithms, we perform codon optimization to enhance translation speed and mRNA stability while avoiding secondary structures that could interfere with the IVT process.
The optimized sequence is cloned into a high-copy plasmid vector. We then perform precise linearization using restriction enzymes, followed by rigorous purification to ensure a "clean" template free of RNases and plasmid debris.
The linearized DNA serves as a template for enzymatic synthesis. We optimize the reaction conditions—including NTP concentrations and buffer components—to maximize yield and ensure the production of full-length hEPO transcripts.
During or immediately following transcription, we apply capping (Cap-1) and poly(A) tailing. This step is critical for protecting the hEPO mRNA from exonuclease degradation and ensuring efficient recruitment of the ribosome.
To remove impurities such as dsRNA, truncated transcripts, and residual enzymes, we utilize high-performance liquid chromatography (HPLC) or tangential flow filtration (TFF). This results in exceptionally pure mRNA with minimal inflammatory potential.
Every lot undergoes stringent testing, including fragment analysis for integrity, concentration measurement, endotoxin assays, and functional testing to confirm hEPO protein expression.
Anemia Therapeutics Development
Our hEPO mRNA serves as a primary tool for developing treatments for chronic kidney disease and chemotherapy-induced anemia. It enables endogenous production of EPO, providing a more stable and natural therapeutic alternative to recombinant protein injections.
Protein Replacement Therapy
As a benchmark model for secreted proteins, hEPO mRNA is used to validate platform technologies for enzyme deficiencies. It allows researchers to study translation efficiency, secretion pathways, and protein folding under physiological conditions.
Non-Viral Delivery System (DDS) Validation
hEPO mRNA is frequently used as a functional reporter to evaluate lipid nanoparticles (LNPs). Researchers precisely measure delivery potency by monitoring serum hEPO levels and reticulocyte counts in animal models following administration.
Regenerative Medicine & Neuroprotection
hEPO mRNA is utilized in research concerning tissue repair and neuroprotection. It facilitates the exploration of treatments for ischemic injury and wound healing by providing transient, localized EPO expression for cellular protection.
Minimal Innate Immunogenicity
By incorporating high-grade N1-methylpseudouridine and utilizing advanced purification methods to remove dsRNA, we ensure our mRNA minimizes the induction of interferon-mediated immune responses.
High Capping Efficiency
Our co-transcriptional capping process consistently achieves >95% Cap-1 incorporation, which is vital for the stability and long-term activity of hEPO mRNA in biological systems.
Customizable Modification Profiles
We offer a wide range of chemical modifications and tailing options, allowing clients to fine-tune the half-life and tissue-specific expression of their hEPO candidates.
Rigorous Quality Assurance
Every batch is accompanied by a detailed certificate of analysis (CoA) including purity, integrity, and safety metrics, ensuring reproducible results for your critical therapeutic research.
"The hEPO mRNA synthesized by CD BioGlyco showed remarkable stability in our in vivo models. We observed a sustained increase in hemoglobin levels that outperformed our previous benchmarks."
— A.H., Biopharmaceutical Company
"We struggled with low yields and high immunogenicity from other suppliers. Switching to CD BioGlyco's HPLC-purified hEPO mRNA made a significant difference in our LNP delivery studies."
— G.H., Innovative Biotech Startup
"The team at CD BioGlyco helped us design a custom UTR sequence that tripled our hEPO expression levels in renal cell lines. Their expertise in the therapeutic nucleic acid development platform is evident in the quality of the final product."
— S.H., Principal Investigator
CD BioGlyco is your dedicated partner for high-performance hEPO mRNA synthesis. By integrating cutting-edge IVT technologies with rigorous purification and glycobiology expertise, we deliver mRNA products that meet the stringent demands of modern therapeutic development. Please feel free to contact us for detailed information, pricing, or to discuss the specific needs of your project.
